Customize
Quick Links
Specialties

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Resources

PER Pulse™ Recaps for Community Practice Connections™: 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice Changing Application

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Foundation Medicine, Inc., Genentech, Incyte, Merck Sharp & Dohme Corp. and NantHealth, Inc.

Community Practice Connections™: 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application

Release Date: March 31, 2017
Expiration Date: March 31, 2018
Media: Internet - based

 

Activity Overview

Community Practice Connections™: 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application features case-based discussion of the application of immune checkpoint inhibitors in several tumor types. Interactive clinical vignettes are followed by short video interviews with leading oncology experts and short summaries of clinical data related to these clinical settings. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians using immunotherapy.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Foundation Medicine, Inc., Genentech, Incyte, Merck Sharp & Dohme Corp. and NantHealth, Inc.

CME/CE Activity Table of Contents

  • Module 1. A Patient With Platinum-Pretreated Bladder
  • Module 2: A Patient With Recurrent Head & Neck Cancer
  • Module 3. Metastatic Lung Cancer (squamous and nonsquamous)
  • Module 4. A Patient With Advanced, Previously Treated Melanoma
  • Posttest

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, educational content/video will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the immunotherapies, and their evolving roles in the treatment of cancer.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain current and evolving mechanistic approaches concerning how the immune system can be targeted in the treatment of cancer.
  • Evaluate clinical trial findings on immuno-oncology strategies and how they can be practically applied to the management of cancer in multiple lines of care.
  • Discuss emerging methods to personalize care via the use of biomarkers and other methods to individualize the use of immuno-oncology strategies.
  • Describe how common and uncommon adverse events, associated with the use of immuno-oncology strategies, can be proactively mitigated and managed.
  • Detail important remaining clinical questions in the field, and highly anticipated ongoing clinical trials, that are evaluating emerging immuno-oncology strategies.

Faculty, Staff, and Planners' Disclosures

Faculty

Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular & Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California, USA

Disclosure: Consultant: Merck, Novartis, Roche; Shareholder: Abraxis, CytomX, Compugen, Five Prime, Kite Pharma

Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
New Haven, CT
 

Disclosure: Grant/Research Support: Oncogenix, Progenics, Johnson and Johnson, Millineum, Celgene, Dendreon, Sanofi, Agenysis, Eli Lilly, Roche Laboratories; Consultant: Bayer, Bellicum, Dendreon, Sanofi Avenitis, Johnson and Johnson, Exelixis, Ferring, Millineum, Medivation, Pfizer, Roche Laboratories, Tyme pharmaceuticals; Shareholder: Bellicum, Tyme

Tanguy Seiwert, MD
Medical Oncologist
The University of Chicago Medicine
Chicago, IL
 
 

Disclosure: Consultant: Amgen, Astra Zeneca, BMS, Celgene, Innate, Jounce, Lilly, Merck, Merck-Serono

Naiyer A Rizvi, MD
Director, Thoracic Oncology
Director, Immunotherapeutics
Price Chair, Clinical Translational Research
Columbia University Medical Center
New York, NY

Disclosure: Consultant: Merck, Roche, BMS, AZ; Shareholder: Gritstone Oncology

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.




PER Pulse™ Recap (1 of 3)

Immunotherapy as a Standard of Care in Lung Cancer

The 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, held December 10, 2016, provided a comprehensive review of key data sets regarding the use of immunotherapies in multiple tumor types. This first of 3 PER Pulse™ Recaps from the meeting focuses on the rapid establishment of immune checkpoint inhibitors in treatment algorithms for patients with non–small cell lung cancer (NSCLC).

The approval of single-agent therapies represents the first phase of lung cancer immunotherapy, although these approvals have had a major impact. In 2016, pembrolizumab received approval, based on data from the KEYNOTE-024 trial, as first-line therapy in patients with PD-L1-positive (≥50%) NSCLC. Also in 2016, the anti–PD-L1 antibody atezolizumab was approved for use in platinum-pretreated patients based on the results of randomized trials, including OAK. Both pembrolizumab and atezolizumab demonstrated superior efficacy compared with standard chemotherapy in the respective settings.

Immunotherapy-based combinations are a key component of the next phase of development, as demonstrated by early phase data. Results of the KEYNOTE-021 trial showed an improvement in overall response rate and progression-free survival with the addition of pembrolizumab to pemetrexed/carboplatin in patients with previously untreated NSCLC and adenocarcinoma histology; the combination regimen is currently under regulatory review. In addition, the blockade of PD-1/PD-L1 and CTLA-4 checkpoints has been explored with the combinations of nivolumab/ipilimumab (CheckMate 012) and durvalumab/tremelimumab. These are currently in phase 3 investigation.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, including downloadable slides from the meeting.




PER Pulse™ Recap (2 of 3)

The Rapid Rise of Immune Checkpoint Inhibitors in Advanced Bladder Cancer

The 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, held December 10, 2016, provided a comprehensive review of key data sets regarding the use of immunotherapies in multiple tumor types. This second of 3 PER Pulse™ Recaps from the meeting focuses on the emergence of immunotherapy in patients with advanced bladder cancer.

The platinum-pretreated setting of advanced bladder cancer has received major attention from developers of immunotherapy, with atezolizumab receiving approval in May 2016, followed by nivolumab in February 2017. At least 3 other antibodies (avelumab, durvalumab, and pembrolizumab) are in regulatory review for patients with platinum-pretreated bladder cancer, with decisions anticipated by mid-2017.

In the frontline setting, immunotherapy is being explored as treatment for patients who are ineligible to receive cisplatin. Currently, atezolizumab and pembrolizumab are in review for this indication, with decisions expected in April 2017 and June 2017, respectively.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, including downloadable slides from the meeting.




PER Pulse™ Recap (3 of 3)

Immunotherapy in Cutaneous Malignancies and Head and Neck Cancer

The 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, held December 10, 2016, provided a comprehensive review of key data sets regarding the use of immunotherapies in multiple tumor types. This third of 3 PER Pulse™ Recaps from the meeting focuses on recent developments with immunotherapy in Merkel cell carcinoma (MCC), melanoma, and head and neck squamous cell carcinoma (HNSCC).

Demonstrating the broad reach of immunotherapy, patients with the relatively uncommon MCC now have avelumab, an anti–PD-L1 antibody, which received accelerated approval from the FDA in March 2017. This indication also applies to patients who have not previously received chemotherapy. The anti–PD-1 antibody, pembrolizumab, has also demonstrated activity as first-line systemic therapy in patients with MCC.

In melanoma, a major developmental frontier is the investigation of novel combinations. These include combinations of immune checkpoint inhibitors with epacadostat, which inhibits the immunosuppressive enzyme indoleamine 2, 3-dioxygenase, as well as combinations with BRAF and MEK inhibitors.

For patients with recurrent/metastatic, platinum-pretreated HNSCC, 2 antibodies were approved in 2016. Pembrolizumab received accelerated approval in August 2016 based on the response rate in the KEYNOTE-012 trial. And in November 2016, nivolumab received approval based on an overall survival benefit compared with investigator’s choice therapy in the CheckMate 141 study.

For additional commentary about these topics and others, visit www.gotoper.com to access more resources from the 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, including downloadable slides from the meeting.








Become a Member

Forgot Password?
Filter By